Literature DB >> 17690939

Hepatic imaging characteristics predict overall survival in hepatocellular carcinoma.

Charles E Woodall1, Charles R Scoggins, Jennifer Loehle, Kadiyala V Ravindra, Kelly M McMasters, Robert C G Martin.   

Abstract

BACKGROUND: Pathologic tumor-related factors, including vascular invasion, remain the only reliable predictor of recurrence and overall survival in hepatocellular cancer (HCC). Other preoperative factors, such as hepatitis status, degree of liver disease (cirrhosis), number of tumors, and size of tumors have been inconsistent in predicting outcome. The aim of this study is to demonstrate that standard radiological imaging characteristics will predict overall survival in HCC.
METHODS: We identified 103 HCC treated in our department from January 1999 to June 2005. All images were reviewed by two blinded physicians and classified into one of three radiological characteristics: pusher/mass forming (well encapsulated without parenchymal violation), invader (non-encapsulated with violation of parenchyma), and hanger/pedunculated (encapsulated with a majority of the lesion suspended from segments II, III, IV b, V, and / or VI).
RESULTS: The study included 61 males and 31 females with a median age of 61 years (range 23 to 90 years), a median of one lesion (range 1-10), a majority with <25% liver involvement, with a median lesion size of 6 cm (range 1 to 22 cm). Surgical therapy included hepatic resection 34 (33%), RFA 23 (22%), and liver transplantation 21 (20%). The distribution of radiological characteristics at initial evaluation was 54% pushers, 41% invaders, and 4% hangers. Median survival for invaders (8.2 months) and hangers (10.0 months) was significantly lower than for pushers (median 29 months) (p = 0.0007).
CONCLUSION: Standard, reproducible radiological characteristics are predictive of outcome in patients with HCC. Greater emphasis on identifying preoperative factors remains imperative to better identify patients' biology and determine which should undergo resection or transplantation.

Entities:  

Mesh:

Year:  2007        PMID: 17690939     DOI: 10.1245/s10434-007-9525-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Melanie B Thomas; Deborah Jaffe; Michael M Choti; Jacques Belghiti; Steven Curley; Yuman Fong; Gregory Gores; Robert Kerlan; Phillipe Merle; Bert O'Neil; Ronnie Poon; Lawrence Schwartz; Joel Tepper; Francis Yao; Daniel Haller; Margaret Mooney; Alan Venook
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

2.  Multi-disciplinary Concurrent Management of Recurrent Hepatocellular Therapy is Superior to Sequential Therapy.

Authors:  Tyler D Fields; Prejesh Philips; Charles R Scoggins; Cliff Tatum; Lawrence Kelly; Kelly M McMasters; Robert C G Martin
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

3.  Enhancement patterns of hepatocellular carcinomas on multiphasicmultidetector row CT: comparison with pathological differentiation.

Authors:  J H Lee; J M Lee; S J Kim; J H Baek; S H Yun; K W Kim; J K Han; B I Choi
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

Review 4.  Pedunculated hepatocellular carcinoma and splenic metastasis.

Authors:  Mao-Lin Yan; Yao-Dong Wang; Zhi-De Lai; Yi-Feng Tian; Hong-Biao Chen; Fu-Nan Qiu; Song-Qiang Zhou
Journal:  World J Gastroenterol       Date:  2009-11-07       Impact factor: 5.742

5.  Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma.

Authors:  David J Pinato; Madhava Pai; Isabella Reccia; Markand Patel; Alexandros Giakoustidis; Georgios Karamanakos; Azelea Rushd; Shiraz Jamshaid; Alberto Oldani; Glenda Grossi; Mario Pirisi; Paul Tait; Rohini Sharma
Journal:  BMC Cancer       Date:  2018-02-20       Impact factor: 4.430

6.  Prediction of prognostic risk factors in hepatocellular carcinoma with transarterial chemoembolization using multi-modal multi-task deep learning.

Authors:  Qiu-Ping Liu; Xun Xu; Fei-Peng Zhu; Yu-Dong Zhang; Xi-Sheng Liu
Journal:  EClinicalMedicine       Date:  2020-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.